申请人:SANOFI
公开号:US05656648A1
公开(公告)日:1997-08-12
The invention relates to the use of a compound of formula: ##STR1## in which Y represents a 3-quinolyl group or a 2-indolyl group of formula: ##STR2## in which: X is chosen from 4-chloro-2,6-dimethoxyphenyl, 2,6-dimethoxy-4-methylphenyl, 2,4,5-trimethoxyphenyl, 4-methyl-2,3,6-trimethoxyphenyl, 2,6-dimethoxy-4-ethylphenyl, 2,4,6-trimethoxy-5-chlorophenyl, 2,4,6-trimethoxy-3-pyridyl, 2,4-dimethoxy-6-methyl-3-pyridyl, 6-chloro-2,4-dimethoxy-5-pyrimidinyl, 2,4,6-trimethoxy-5-pyrimidinyl, 5-chloro-2,4-dimethoxyphenyl, 5-chloro-2-methoxy-4-methylphenyl, 2,5-dimethoxy-4-methylphenyl, 4-trifluoromethyl-2,6-dimethoxyphenyl, 2,4-dimethoxy-5-methylphenyl, 5-ethyl-2,4-dimethoxyphenyl and 2,4-dimethoxyphenyl groups; Z represents H, a C.sub.1 -C.sub.4 -alkyl or a benzyl; for combating complaints whose treatment necessitates a stimulation of the cholecystokinin receptors by a total or partial agonist effect.
该发明涉及使用以下公式的化合物:##STR1##其中Y代表公式的3-喹啉基团或2-吲哚基团:##STR2##其中:X选择自4-氯-2,6-二甲氧基苯基,2,6-二甲氧基-4-甲基苯基,2,4,5-三甲氧基苯基,4-甲基-2,3,6-三甲氧基苯基,2,6-二甲氧基-4-乙基苯基,2,4,6-三甲氧基-5-氯苯基,2,4,6-三甲氧基-3-吡啶基,2,4-二甲氧基-6-甲基-3-吡啶基,6-氯-2,4-二甲氧基-5-嘧啶基,2,4,6-三甲氧基-5-嘧啶基,5-氯-2,4-二甲氧基苯基,5-氯-2-甲氧基-4-甲基苯基,2,5-二甲氧基-4-甲基苯基,4-三氟甲基-2,6-二甲氧基苯基,2,4-二甲氧基-5-甲基苯基,5-乙基-2,4-二甲氧基苯基和2,4-二甲氧基苯基基团;Z代表H,C.sub.1-C.sub.4烷基或苄基;用于对抗需要通过全或部分激动胆囊收缩素受体的药理作用来治疗的不适症状。